Medistep Healthcare IPO is a book-built issue aiming to raise ₹16.10 crore. It comprises a fresh issue of 0.38 crore equity shares aggregating to ₹16.10 crore. The bidding window was open from August 8, 2025, to August 12, 2025, with the IPO allotment to be finalised on August 13, 2025. J Medistep Healthcare is scheduled to list on NSE SME on August 18, 2025.
The IPO was priced at ₹43 per share with a lot size of 3,000 shares. The public issue received bids for 1,35,85,11,000 shares against 35,55,000 shares available for the public, resulting in an overall subscription of 382.14 times. Retail investors led the demand, subscribing 461.11 times, followed by NIIs at 289.15 times.
Medistep Healthcare’s ₹16.10 crore IPO, priced at ₹43 per share, was subscribed 382.14 times overall. The issue is entirely a fresh issue of 37.44 lakh equity shares aggregating to ₹16.10 crore. Bidding took place from August 8 to August 12, 2025, with the allotment to be finalised on August 13, 2025. Retail investors subscribed 461.11 times and NIIs 289.15 times. Listing is expected on August 18, 2025.
The table below breaks down the Medistep Healthcare share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| Market Maker Shares | 1,89,000 (5.05%) |
| NII (HNI) Shares | 17,76,000 (47.44%) |
| Retail Shares | 17,79,000 (47.52%) |
| Total Shares | 37,44,000 (100.00%) |
Data Source: NSE
| Category | Subscription (times) |
| Non-Institutional Investors | 289.15 |
| Retail Individual Investors | 461.11 |
| Total shares | 382.14 |
Note: The subscription details are as of August 12, 2025
Medistep Healthcare Limited, incorporated in June 2023, is a pharmaceutical company engaged in the production of sanitary pads, energy powders, and a wide range of pharmaceutical, nutraceutical, intimate care, and surgical products. Operating as a public, non-government company, Medistep is committed to maintaining high quality standards while aiming to expand its product offerings.
Their product portfolio includes high quality sanitary pads addressing feminine hygiene, energy powders designed to revitalise consumers, essential pharmaceutical products traded for better accessibility, nutraceuticals that combine nutrition with pharmaceuticals for overall wellness, intimate care products for personal hygiene, and surgical supplies supporting healthcare professionals.
As of December 30, 2024, the company reported annualised revenues of ₹45 crore and a profit after tax (PAT) of ₹4.08 crore. With a workforce of 9 full-time employees as of December 28, 2024, additional labour requirements are met through daily wage workers, with no contract employees on payroll.
Financially, the company demonstrated robust growth, with revenues increasing by 27% and PAT rising by 25% between the financial years ending March 31, 2024, and March 31, 2025.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Aug 12, 2025, 9:24 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
